FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2349190322> ?p ?o ?g. }

• W2349190322 endingPage "37713" @default.
• W2349190322 startingPage "37693" @default.
• W2349190322 abstract "Elevated expression of Survivin correlates with poor prognosis, tumor recurrence, and drug resistance in various human cancers, including non-small cell lung cancer (NSCLC). The underlying mechanism of Survivin upregulation in cancer cells remains elusive. To date, no Survivin-targeted therapy has been approved for cancer treatment. Here, we explored the molecular basis resulting in Survivin overexpression in NSCLC and investigated the antitumor activity of the class I HDAC inhibitor entinostat in combination with paclitaxel. Our data showed that entinostat significantly enhanced paclitaxel-mediated anti-proliferative/anti-survival effects on NSCLC cells in vitro and in vivo. Mechanistically, entinostat selectively decreased expression of Survivin via induction of miR-203 (in vitro and in vivo) and miR-542-3p (in vitro). Moreover, analysis of NSCLC patient samples revealed that the expression levels of miR-203 were downregulated due to promoter hypermethylation in 45% of NSCLC tumors. In contrast, increased expression of both DNA methytransferase I (DNMT1) and Survivin was observed and significantly correlated with the reduced miR-203 in NSCLC. Collectively, these data shed new lights on the molecular mechanism of Survivin upregulation in NSCLC. Our findings also support that the combinatorial treatments of entinostat and paclitaxel will likely exhibit survival benefit in the NSCLC patients with overexpression of DNMT1 and/or Survivin. The DNMT1-miR-203-Survivin signaling axis may provide a new avenue for the development of novel epigenetic approaches to enhance the chemotherapeutic efficacy against NSCLC." @default.
• W2349190322 created "2016-06-24" @default.
• W2349190322 creator A5002426002 @default.
• W2349190322 creator A5009591001 @default.
• W2349190322 creator A5015865769 @default.
• W2349190322 creator A5016058970 @default.
• W2349190322 creator A5017176254 @default.
• W2349190322 creator A5018244700 @default.
• W2349190322 creator A5020883194 @default.
• W2349190322 creator A5027061078 @default.
• W2349190322 creator A5034643467 @default.
• W2349190322 creator A5041529343 @default.
• W2349190322 creator A5043479363 @default.
• W2349190322 creator A5045554538 @default.
• W2349190322 creator A5048009965 @default.
• W2349190322 creator A5048727442 @default.
• W2349190322 creator A5054342681 @default.
• W2349190322 creator A5068283151 @default.
• W2349190322 creator A5071037763 @default.
• W2349190322 creator A5071316360 @default.
• W2349190322 creator A5071991426 @default.
• W2349190322 creator A5079394106 @default.
• W2349190322 creator A5081369124 @default.
• W2349190322 creator A5086321795 @default.
• W2349190322 date "2016-05-10" @default.
• W2349190322 modified "2023-10-18" @default.
• W2349190322 title "MicroRNA-mediated epigenetic targeting of Survivin significantly enhances the antitumor activity of paclitaxel against non-small cell lung cancer" @default.
• W2349190322 cites W1611604148 @default.
• W2349190322 cites W1795095761 @default.
• W2349190322 cites W1924319313 @default.
• W2349190322 cites W1966116761 @default.
• W2349190322 cites W1969628021 @default.
• W2349190322 cites W1972169216 @default.
• W2349190322 cites W1979101646 @default.
• W2349190322 cites W1980937575 @default.
• W2349190322 cites W1986397853 @default.
• W2349190322 cites W1997961866 @default.
• W2349190322 cites W1999605095 @default.
• W2349190322 cites W1999804975 @default.
• W2349190322 cites W2016431114 @default.
• W2349190322 cites W2017290745 @default.
• W2349190322 cites W2029243859 @default.
• W2349190322 cites W2037139573 @default.
• W2349190322 cites W2041686632 @default.
• W2349190322 cites W2043879899 @default.
• W2349190322 cites W2045986053 @default.
• W2349190322 cites W2055397209 @default.
• W2349190322 cites W2066081464 @default.
• W2349190322 cites W2073869832 @default.
• W2349190322 cites W2075557071 @default.
• W2349190322 cites W2078374613 @default.
• W2349190322 cites W2090029719 @default.
• W2349190322 cites W2095229706 @default.
• W2349190322 cites W2096952961 @default.
• W2349190322 cites W2099407732 @default.
• W2349190322 cites W2103576580 @default.
• W2349190322 cites W2106241374 @default.
• W2349190322 cites W2106787323 @default.
• W2349190322 cites W2107846614 @default.
• W2349190322 cites W2111547058 @default.
• W2349190322 cites W2112725925 @default.
• W2349190322 cites W2117531315 @default.
• W2349190322 cites W2120272649 @default.
• W2349190322 cites W2120683603 @default.
• W2349190322 cites W2123064897 @default.
• W2349190322 cites W2123973342 @default.
• W2349190322 cites W2128039856 @default.
• W2349190322 cites W2139056019 @default.
• W2349190322 cites W2145835533 @default.
• W2349190322 cites W2147057201 @default.
• W2349190322 cites W2152095899 @default.
• W2349190322 cites W2158859033 @default.
• W2349190322 cites W2162674813 @default.
• W2349190322 cites W2168465557 @default.
• W2349190322 cites W2169961966 @default.
• W2349190322 cites W2194026923 @default.
• W2349190322 cites W2219978888 @default.
• W2349190322 cites W2806575069 @default.
• W2349190322 cites W307194245 @default.
• W2349190322 cites W3190412754 @default.
• W2349190322 cites W4238038536 @default.
• W2349190322 doi "https://doi.org/10.18632/oncotarget.9264" @default.
• W2349190322 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5122342" @default.
• W2349190322 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27177222" @default.
• W2349190322 hasPublicationYear "2016" @default.
• W2349190322 type Work @default.
• W2349190322 sameAs 2349190322 @default.
• W2349190322 citedByCount "26" @default.
• W2349190322 countsByYear W23491903222017 @default.
• W2349190322 countsByYear W23491903222018 @default.
• W2349190322 countsByYear W23491903222019 @default.
• W2349190322 countsByYear W23491903222020 @default.
• W2349190322 countsByYear W23491903222021 @default.
• W2349190322 countsByYear W23491903222023 @default.
• W2349190322 crossrefType "journal-article" @default.
• W2349190322 hasAuthorship W2349190322A5002426002 @default.
• W2349190322 hasAuthorship W2349190322A5009591001 @default.
• W2349190322 hasAuthorship W2349190322A5015865769 @default.

• next